Search

everythinglearnresearchcommunity

for

Search:↓

The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

A new compound was effective for imaging prostate cancer in rats.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.

The treatment combination is effective and generally safe for lung cancer.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Cetuximab often causes skin rashes, and managing these is important for cancer treatment.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.

Vismodegib is effective for basal cell carcinoma but has severe side effects.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Oral tofacitinib may effectively regrow hair in children with alopecia areata unresponsive to other treatments.

MK-5108 is safe and shows potential against tumors, especially alone.

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Cytarabine can cause multiple organ toxicities, especially neurotoxicity, but better research methods are needed to fully understand and predict these effects.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

The treatment was effective and tolerable for advanced gastric cancer.

Cyproterone acetate treatment is safe and causes mild feminization, which increases with added estrogen.

Adding chemotherapy to tamoxifen improves survival for older breast cancer patients with positive nodes.

Intralesional chemotherapy with 5-fluorouracil and methotrexate may worsen keratoacanthoma-type skin cancer in transplant patients.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.